Press Releases

Adelaide, South Australia, October 10, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufacture. Centivax is developing Cent-Flu, a universal influenza vaccine, consisting of a proprietary multivalent mixture of 22

Adelaide, South Australia, September 25, 2024/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells.    EnGeneIC’s mission is to

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx Adelaide, South Australia, June 3, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx’s Recombination Based Plasmid System (RBPS) technology with BioCina’s CDMO clients. RBPS is a cutting-edge technology

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors  (Miami and Perth, Australia, March 5, 2024) Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board. “We are thrilled to have Mark

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to

Adelaide, South Australia, November 6, 2023, BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such

ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T)

MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $5.0m AUD grant under the Federal Government’s Medical Research Future Fund (MRFF) Grants scheme to fund work with its industry partners to develop enabling technologies for manufacture

(MIAMI and ADELAIDE March 14, 2023) BioCina, a leading contract development and manufacturing organization (CDMO) has appointed Mark W. Womack as CEO. Womack will be responsible for the continued growth, commercial strategy and organizational culture of BioCina. This follows the appointment of founding CEO, Ian Wisenberg, to Executive Chairman of BioCina Board of Directors. “Over